known differences in radiation response, i.e. radiosensitive types such as seminomas and resistant types as chondrosarcomas. We hypothesized that the number of residual cH2AX foci corresponds to the expected tumour radiation sensitivity. In addition, in order to enhance clinical practicability for future studies the data were used for simulations to test the robustness of the method when omitting dose levels. Materials and methods Collection and cultivation of patient-derived tumour specimensThe study has been approved by the Ethics Committee of the Medical Faculty of the University of Tübingen (426/2013BO1). All the patients included in the study were untreated prior to surgical procedure. During collection and cultivation tumour tissues were kept in Dulbecco's MEM culture medium supplemented with 2% HEPES, 1% Na-pyruvate, 1% non-essential amino acids, 1% penicillin streptomycin (all Biochrom AG, Berlin, Germany) and 10% FBS (PAN Biotech GmbH, Aidenbach, Germany). Fresh tumour material was retrieved from surgical specimens and placed in 50 ml Falcon tubes (Becton Dickinson International, Heidelberg, Germany) containing 15 ml culture medium. Tumour specimens were transported to the laboratory and subsequently cut manually with the use of surgical forceps (BD027R, B. BRAUN, Aesculap, Tuttlingen, Germany) and scalpels (FEATHER Safety Razor Co., Ltd., Osaka, Japan Number 23) into approximately 2-3 mm slices before being placed in petri dishes (3.5 cm diameter) coated with a 1.5% agarose layer (A9539, Sigma-Aldrich, Germany) containing 3 ml culture media. During all incubation times the petri-dishes were kept in 95% humidified atmosphere at 37 _C and 5% CO2. For the purpose of the study tumour material from a total of 25 patient tumours with 10 different tumour histologies was collected (Table 1; n = 3 seminomas, n = 1 chondrosarcoma, n = 3 urinary bladder carcinomas (Ca), n = 3 colorectal Ca (2 colon Ca + 1 rectum), n = 3 breast Ca, n = 1 hepatocellular Ca, n = 3 renal cell Ca, n = 3 prostate Ca, n = 4 glioblastoma multiforme (GBM) and n = 2 cervix Ca). In one GBM patient, the specimen was removed from the analysis because in the 0 Gy sample there was no viable tumour part (based on morphological criteria and BrdU positivity) and no estimation of the background foci could be performed. Histology and selection of malignant cells for analysis were confirmed by an experienced pathologist (M.S.).Experimental design for evaluation of cH2AX foci in ex vivo irradiated patient-derived tumour specimensThe experimental design has been previously described [45]. Briefly, after initial cultivation for 24 h, the tumour specimens were irradiated typically with 0, 2, 4, 6, 8 Gy single doses (200 kV, RS225 research system Gulmay Medical LTD, Surrey, England; 15 mA; 0.5 mm Cu; dose rate _1 Gy/min). In two tumours, additional doses were delivered to the seminoma sample (#1) doses of 3 and 5 Gy and GBM (#1) 10
Our data confirm safety and efficacy of RT in preventing HO, especially in high-risk patients, preferring a single fraction of 7 Gy.
The aim of this study was to evaluate local control, survival and toxicity profile of a consecutive cohort of early-stage breast cancer (EBC) patients treated with adjuvant hypofractionated radiotherapy (HF) with no boost delivered to the lumpectomy cavity, after breast-conserving surgery (BCS). Between 2005 and 2015, a total of 493 women affected with EBC were treated with HF (46 Gy/20 fractions or 40.05 Gy/15 fractions) to the whole breast without boost to tumor bed, because of age and/or favorable tumor characteristics. The primary endpoint was 5-year actuarial local control (LC); secondary endpoints included survival, toxicity profile and cosmesis. Median follow-up was 57 months (range 6-124). Actuarial 5-year overall, cancer-specific, disease-free survival and LC were 96.3, 98.9, 97.8 and 98.6 %, respectively. On multivariate analysis, tumor stage (T1 vs. T2) and hormonal status (positive vs. negative estrogen receptors) were significantly correlated with LC. Only 2 % of patients experienced ≥G3 acute skin toxicity. Late toxicity was mild with only 1 case of G3 fibrosis. Most of the patients (95 %) had good-excellent cosmetic results. HF to the whole breast with no boost delivered to the tumor bed is a safe and effective option for a population of low-risk breast cancer patients after BCS, with excellent 5-year LC, mild toxicity profile and promising cosmetic outcome. A subgroup of patients with larger tumors and/or with no estrogen receptor expression may potentially benefit from treatment intensification with a boost dose to the lumpectomy cavity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.